• +1-646-491-9876
    • +91-20-67278686

    Search

    Cancer Pain Pipeline Review H1 2017

    Cancer Pain Pipeline Review H1 2017

    • Report Code ID: RW0001799279
    • Category Pharmaceuticals
    • No. of Pages 131
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Cancer Pain - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H1 2017, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.

    Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 8, 5, 3, 1, 20, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

    Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 5
    Cancer Pain - Overview 6
    Cancer Pain - Therapeutics Development 7
    Cancer Pain - Therapeutics Assessment 17
    Cancer Pain - Companies Involved in Therapeutics Development 27
    Cancer Pain - Drug Profiles 45
    Cancer Pain - Dormant Projects 113
    Cancer Pain - Discontinued Products 116
    Cancer Pain - Product Development Milestones 117
    Appendix 125

    List of Tables

    Number of Products under Development for Cancer Pain, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, H1 2017
    Cancer Pain - Pipeline by AngioChem Inc, H1 2017
    Cancer Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
    Cancer Pain - Pipeline by Aphios Corp, H1 2017
    Cancer Pain - Pipeline by AstraZeneca Plc, H1 2017
    Cancer Pain - Pipeline by ChironWells GmbH, H1 2017
    Cancer Pain - Pipeline by Colby Pharmaceutical Company, H1 2017
    Cancer Pain - Pipeline by ConSynance Therapeutics Inc, H1 2017
    Cancer Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Cancer Pain - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Cancer Pain - Pipeline by Dompe Farmaceutici SpA, H1 2017
    Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corp, H1 2017
    Cancer Pain - Pipeline by Grunenthal GmbH, H1 2017
    Cancer Pain - Pipeline by GW Pharmaceuticals Plc, H1 2017
    Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017
    Cancer Pain - Pipeline by Immupharma Plc, H1 2017
    Cancer Pain - Pipeline by Insys Therapeutics Inc, H1 2017
    Cancer Pain - Pipeline by IntelGenx Corp, H1 2017
    Cancer Pain - Pipeline by iX Biopharma Ltd, H1 2017
    Cancer Pain - Pipeline by Kancera AB, H1 2017
    Cancer Pain - Pipeline by Klaria Pharma Holding AB, H1 2017
    Cancer Pain - Pipeline by Komipharm International Co Ltd, H1 2017
    Cancer Pain - Pipeline by KPI Therapeutics Inc, H1 2017
    Cancer Pain - Pipeline by Medlab Clinical Ltd, H1 2017
    Cancer Pain - Pipeline by Nanomerics Ltd, H1 2017
    Cancer Pain - Pipeline by Neurocentrx Pharma Ltd, H1 2017
    Cancer Pain - Pipeline by Nippon Kayaku Co Ltd, H1 2017
    Cancer Pain - Pipeline by Orion Oyj, H1 2017
    Cancer Pain - Pipeline by Pain Therapeutics Inc, H1 2017
    Cancer Pain - Pipeline by Pfizer Inc, H1 2017
    Cancer Pain - Pipeline by Pharmaleads SA, H1 2017
    Cancer Pain - Pipeline by Recordati SpA, H1 2017
    Cancer Pain - Pipeline by Ribomic Inc, H1 2017
    Cancer Pain - Pipeline by Trillium Therapeutics Inc, H1 2017
    Cancer Pain - Pipeline by Virobay Inc, H1 2017
    Cancer Pain - Pipeline by WEX Pharmaceuticals Inc, H1 2017
    Cancer Pain - Dormant Projects, H1 2017
    Cancer Pain - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Cancer Pain - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Cancer Pain - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Cancer Pain, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Alexza Pharmaceuticals Inc
    AngioChem Inc
    Aoxing Pharmaceutical Company Inc
    Aphios Corp
    AstraZeneca Plc
    ChironWells GmbH
    Colby Pharmaceutical Company
    ConSynance Therapeutics Inc
    Daewoong Pharmaceutical Co Ltd
    Daiichi Sankyo Company Ltd
    Dompe Farmaceutici SpA
    Fujimoto Pharmaceutical Corp
    Grunenthal GmbH
    GW Pharmaceuticals Plc
    Hisamitsu Pharmaceutical Co Inc
    Immupharma Plc
    Insys Therapeutics Inc
    IntelGenx Corp
    iX Biopharma Ltd
    Kancera AB
    Klaria Pharma Holding AB
    Komipharm International Co Ltd
    KPI Therapeutics Inc
    Medlab Clinical Ltd
    Nanomerics Ltd
    Neurocentrx Pharma Ltd
    Nippon Kayaku Co Ltd
    Orion Oyj
    Pain Therapeutics Inc
    Pfizer Inc
    Pharmaleads SA
    Recordati SpA
    Ribomic Inc
    Trillium Therapeutics Inc
    Virobay Inc
    WEX Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//cancer-pain-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//cancer-pain-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//cancer-pain-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments